2022
24‐Month follow‐up of randomized controlled trial of guided‐self‐help for loss‐of‐control eating after bariatric surgery
Grilo CM, Ivezaj V, Duffy AJ, Gueorguieva R. 24‐Month follow‐up of randomized controlled trial of guided‐self‐help for loss‐of‐control eating after bariatric surgery. International Journal Of Eating Disorders 2022, 55: 1521-1531. PMID: 36054766, DOI: 10.1002/eat.23804.Peer-Reviewed Original ResearchConceptsBariatric surgeryHELP treatmentWeight gainLong-term effectsSuboptimal long-term outcomesModest weight lossProportion of patientsBariatric surgery outcomesSubgroup of patientsLong-term outcomesSignificant weight gainSubstantial weight gainEating-disorder psychopathologyPostoperative interventionsAdjunctive treatmentTreat analysisSurgery outcomesSpecialist treatmentLOC eatingPatientsSurgeryWeight lossTrial testingPosttreatmentTreatment
2017
A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia
Gunduz‐Bruce H, Kenney J, Changlani S, Peixoto A, Gueorguieva R, Leone C, Stachenfeld N. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2017, 102: 587-597. PMID: 28294453, DOI: 10.1113/ep086212.Peer-Reviewed Original ResearchConceptsSubgroup of patientsHealthy control subjectsNMDA receptorsControl subjectsDepressed patientsAVP releaseAnimal studiesSchizophrenic subjectsTranslational approachVivo evidenceRecent clinical trialsNMDA receptor functionPlasma arginine vasopressin concentrationNMDA receptor activityHypertonic saline infusionNMDA antagonist ketamineArginine vasopressin concentrationHypertonic salineInverse associationClinical trialsHealthy controlsSaline infusionGlutamate signalingSchizophrenic patientsVasopressin concentration
2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroupsASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia
Shivarov V, Gueorguieva R, Ivanova M, Tiu RV. ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia. Leukemia & Lymphoma 2015, 56: 1881-1883. PMID: 25308295, DOI: 10.3109/10428194.2014.974596.Peer-Reviewed Original Research
2013
DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leukemia Research 2013, 37: 1445-1450. PMID: 23962568, DOI: 10.1016/j.leukres.2013.07.032.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAML patientsEuropean Leukemia NetDNMT3A mutationsIndependent adverse prognostic factorPoor prognosis biomarkerAdverse prognostic factorSubgroup of patientsPotential prognostic valueHigh-risk genotypesRecurrent molecular aberrationsDNMT3A mutational statusShorter OSShorter RFSYounger patientsPrognostic factorsRisk stratificationWorse prognosisPrognostic valueAML subtypesMyeloid leukemiaPrognosis biomarkerPatientsMolecular aberrationsRisk genotypes